The estimated Net Worth of Srdjan R. Stankovic is at least $6.52 Milión dollars as of 19 November 2022. Srdjan Stankovic owns over 6,250 units of Acadia Pharmaceuticals Inc stock worth over $1,006,142 and over the last 9 years he sold ACAD stock worth over $426,592. In addition, he makes $5,088,270 as President at Acadia Pharmaceuticals Inc.
Sign up
Srdjan Stankovic ACAD stock SEC Form 4 insiders trading
Srdjan has made over 19 trades of the Acadia Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 6,250 units of ACAD stock worth $99,688 on 19 November 2022.
The largest trade he's ever made was exercising 154,019 units of Acadia Pharmaceuticals Inc stock on 20 April 2020 worth over $3,032,634. On average, Srdjan trades about 14,576 units every 38 days since 2015. As of 19 November 2022 he still owns at least 63,081 units of Acadia Pharmaceuticals Inc stock.
You can see the complete history of Srdjan Stankovic stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Srdjan Stankovic biography
Dr. Srdjan R. Stankovic M.D. serves as President of the Company. He has served as our President since November 2018. Dr. Stankovic previously served as our Executive Vice President, Head of Research and Development and has been with our company since November 2015. With a background in clinical and academic psychiatry, Dr. Stankovic brings over 20 years of executive level experience in drug development and clinical and medical affairs. Dr. Stankovic has built and led multidisciplinary teams for small molecules and biologics in therapeutic areas including neurology, psychiatry, oncology, cardiology and pain. He has led teams to achieve approvals of KEPPRA®, FENTORA®, TREANDA®, NUVIGIL® and ARISTADA™. Prior to joining our company, Dr. Stankovic served as Senior Vice President of Clinical Development and Medical Affairs at Alkermes plc. from 2013 to 2015. Prior to Alkermes, he held the position of Senior Vice President and Head of Global Clinical Development for Teva Pharmaceuticals Ltd. He was appointed to this role following Teva’s acquisition of Cephalon, Inc. where he served as Senior Vice President, Worldwide Clinical Research. Dr. Stankovic also served as Senior Vice President, Medical Affairs and Clinical Development CNS at Forest Laboratories, Inc. and held executive positions in research and development at Neurogen Corporation, Johnson and Johnson, and UCB. Dr. Stankovic received his M.D. from the University of Belgrade and holds a Master of Science in public health from the University of Alabama at Birmingham.
What is the salary of Srdjan Stankovic?
As the President of Acadia Pharmaceuticals Inc, the total compensation of Srdjan Stankovic at Acadia Pharmaceuticals Inc is $5,088,270. There are 1 executives at Acadia Pharmaceuticals Inc getting paid more, with Stephen Davis having the highest compensation of $7,631,250.
How old is Srdjan Stankovic?
Srdjan Stankovic is 63, he's been the President of Acadia Pharmaceuticals Inc since 2018. There are 2 older and 14 younger executives at Acadia Pharmaceuticals Inc. The oldest executive at Acadia Pharmaceuticals Inc is Edmund Harrigan, 67, who is the Independent Director.
What's Srdjan Stankovic's mailing address?
Srdjan's mailing address filed with the SEC is C/O ACADIA PHARMACEUTICALS INC., 12830 EL CAMINO REAL, SUITE 400, SAN DIEGO, CA, 92130.
Insiders trading at Acadia Pharmaceuticals Inc
Over the last 20 years, insiders at Acadia Pharmaceuticals Inc have traded over $21,409,958 worth of Acadia Pharmaceuticals Inc stock and bought 29,279,665 units worth $647,484,672 . The most active insiders traders include Bros. Advisors Lp14159, L.P..., Bros. Advisors Lp667, L.P.B... a Carl L Gordon. On average, Acadia Pharmaceuticals Inc executives and independent directors trade stock every 17 days with the average trade being worth of $2,248,934. The most recent stock trade was executed by Mark C. Schneyer on 16 August 2024, trading 9,733 units of ACAD stock currently worth $148,720.
What does Acadia Pharmaceuticals Inc do?
acadia pharmaceuticals (nasdaq: acad) is a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in related central nervous system (cns) disorders. all of acadia's product candidates emanate from internal discoveries. we believe that they offer innovative therapeutic approaches that may provide significant advantages relative to current therapies. acadia’s history is rooted in science and strong leadership in cns research. our proprietary drug discovery platform has led to a portfolio of drug candidates with large unmet needs. since the beginning, we have been dedicated to discovering, developing and commercializing innovative therapies that improve the lives of patients suffering from such disorders. acadia is headquartered in san diego. the city represents the second largest biotechnology industry cluster in the united states, home to over 400 companies, as well as the salk institute for biological studies
What does Acadia Pharmaceuticals Inc's logo look like?
Complete history of Srdjan Stankovic stock trades at Acadia Pharmaceuticals Inc
Acadia Pharmaceuticals Inc executives and stock owners
Acadia Pharmaceuticals Inc executives and other stock owners filed with the SEC include:
-
Stephen Davis,
Director and Chief Executive Officer -
Srdjan Stankovic,
President -
Michael Yang,
Executive Vice President, Chief Commercial Officer -
Elena Ridloff,
Executive Vice President, Chief Financial Officer -
Austin Kim,
Executive Vice President, General Counsel, and Secretary -
Stephen R. Davis J.D.,
CEO & Director -
Dr. Srdjan R. Stankovic,
Pres -
Austin D. Kim,
Exec. VP, Gen. Counsel & Sec. -
Daniel Soland,
Independent Director -
James Daly,
Independent Director -
Edmund Harrigan,
Independent Director -
Stephen Biggar,
Independent Chairman of the Board -
Laura Brege,
Independent Director -
Julian Baker,
Independent Director -
Mark Johnson,
Vice President, Investor Relations -
Elizabeth Garofalo,
Director -
James Kihara,
Principal Accounting Officer -
Ponni Subbiah,
Senior Vice President, Global Head of Medical Affairs and Chief Medical Officer -
Mark Schneyer,
Senior Vice President, Business Development and Chief Business Officer -
Stephanie Fagan,
Senior Vice President - Corporate Affairs, Chief Communications Officer -
Gudarz Davar,
Executive Vice President - Head of Research and Development -
Julie Fisher,
Sr. VP of Marketing & Commercial Strategy -
Dr. Kathie M. Bishop Ph.D.,
Sr. VP, Chief Scientific Officer & Head of Rare Disease -
Bob Mischler,
Sr. VP of Strategy & Technology Operations -
James K. Kihara,
VP, Corp. Controller & Principal Accounting Officer -
Brendan Teehan,
Exec. VP, COO & Head of Commercial -
Bros. Advisors Lpbaker Feli...,
-
Mary Ann Gray,
Director -
Terrence O Moore,
EVP, CHIEF COMMERCIAL OFFICER -
L.P.667, L.P.Baker Bros. Ad...,
-
Leslie L Iversen,
-
Bros. Advisors Lp667, L.P.B...,
-
Bros. Advisors Lp14159, L.P...,
-
Todd S. Young,
EVP AND CFO -
Roger Mills,
Executive VP, Development -
Uli Hacksell,
Chief Executive Officer -
Michael T Borer,
Director -
Thomas H Aasen,
VP, CFO, Sec. Treas. -
Lester J Ph D Kaplan,
Director -
Torsten Rasmussen,
Director -
Robert E Davis,
Exec. VP, Drug Discovery -
William Mc Dowall Wells,
-
Bros Advisors Llcbaker Feli...,
-
Bioscience Partners Iv Lpmr...,
-
Osch Martien Van,
Director -
Bioscience Partners Iv Lpob...,
-
Carl L Gordon,
Director -
Felixbaker Julianbaker Bros...,
-
Mark R Brann,
Pres., Chf. Scientific Officer -
Alan Walton,
Director -
Glenn Baity,
EVP AND GC -
Bo Ragnar Tolf,
VP Chm/Mng Dir ACADIA Phrm A/S -
Gordon M Binder,
Director -
Brian Lundstrom,
Sr. VP. Business Development -
John Joseph Kaiser,
VP, Strat. Mrkting & Com. Dev. -
Adora Ndu,
-
Brendan Teehan,
EVP, COO, HEAD OF COMMERCIAL -
Douglas J Williamson,
Executive VP, Research & Dev -
Bros. Advisors Lp667, L.P.B...,
-
Jennifer J Rhodes,
EVP, CHIEF LEGAL OFFICER, SEC -
Elizabeth H.Z. Thompson,
EVP, Head of Research & Dev